Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hein Putter

Showing results (501-510 of 512) with videos related to

Pageof 52
Sort By:
The Lancet. Oncology|May 3, 2024
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trialsFamke C Wakkerman, Jiqing Wu, Hein Putter, et al.
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 1, 2026
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trialAnne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
The Lancet. Oncology|December 25, 2025
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trialAnne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 13, 2020
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancerAnne Sophie V M van den Heerik, Nanda Horeweg, Remi A Nout, et al.
The Lancet. Gastroenterology & Hepatology|August 16, 2024
Indocyanine green near-infrared fluorescence bowel perfusion assessment to prevent anastomotic leakage in minimally invasive colorectal surgery (AVOID): a multicentre, randomised, controlled, phase 3 trialRobin A Faber, Ruben P J Meijer, Daphne H M Droogh, et al.
Bone Marrow Transplantation|March 9, 2023
Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)Riccardo Saccardi, Hein Putter, Dirk-Jan Eikema, et al.
Bone Marrow Transplantation|October 23, 2019
Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)John A Snowden, Riccardo Saccardi, Kim Orchard, et al.
Pageof 52

Showing results (501-510 of 512) with videos related to

Sort By:
Pageof 52
The Lancet. Oncology|May 3, 2024
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trialsFamke C Wakkerman, Jiqing Wu, Hein Putter, et al.
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 1, 2026
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trialAnne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
The Lancet. Oncology|December 25, 2025
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trialAnne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 13, 2020
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancerAnne Sophie V M van den Heerik, Nanda Horeweg, Remi A Nout, et al.
The Lancet. Gastroenterology & Hepatology|August 16, 2024
Indocyanine green near-infrared fluorescence bowel perfusion assessment to prevent anastomotic leakage in minimally invasive colorectal surgery (AVOID): a multicentre, randomised, controlled, phase 3 trialRobin A Faber, Ruben P J Meijer, Daphne H M Droogh, et al.
Bone Marrow Transplantation|March 9, 2023
Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)Riccardo Saccardi, Hein Putter, Dirk-Jan Eikema, et al.
Bone Marrow Transplantation|October 23, 2019
Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)John A Snowden, Riccardo Saccardi, Kim Orchard, et al.
Pageof 52